Scholars@Duke
Annick Desjardins

Annick Desjardins

Professor of Neurosurgery
Neurosurgery, Neuro-Oncology
annick.desjardins@duke.edu
Duke Box 3624, Durham, NC 27710
the Preston Robert Tisch Brain, Rm. 047 Baker House, DUMC 3624, Durham, NC 27710

Scholarly Works - Journal articles

STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.

Journal article J Clin Oncol · March 10, 2026 PURPOSE: STELLAR (ClinicalTrials.gov identifier: NCT02796261) was a phase III, randomized, open-label trial of eflornithine + lomustine versus lomustine monotherapy in patients with recurrent grade 3 astrocytoma. METHODS: At trial initiation, eligibility c ... Full text Link to item Cite

Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration.

Journal article Cancer Immunol Res · February 3, 2026 Tumor-draining lymph nodes are a pivotal site for antitumor T-cell priming. However, their mechanistic roles in cancer immune surveillance and immunotherapy response remain poorly defined. Intratumor (IT) virotherapy generates antitumor T-cell immunity thr ... Full text Link to item Cite

Clinical trial of feasibility for mindfulness intervention for patients with newly diagnosed high grade glioma.

Journal article J Neurooncol · November 5, 2025 PURPOSE: With a bleak prognosis for malignant glioma, maintaining quality of life (QoL) and decreasing distress are essential in patient clinical care. Mindfulness meditation is a mind-body therapy that is being investigated as a non-pharmacological strate ... Full text Open Access Link to item Cite

A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma.

Journal article Sci Rep · October 23, 2025 Many cancers evade immunosurveillance by downregulating surface major histocompatibility class (MHC)-I. Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes MHC-I degradation and is elevated in glioma. Evolocumab is a clinically approved PCSK9 in ... Full text Open Access Link to item Cite

Response Assessment in Neuro-Oncology (RANO) 2009-2025: Broad scope and implementation-A progress report.

Journal article Neuro Oncol · October 14, 2025 Since its first activities in 2008 and 2009, the Response Assessment in NeuroOncology (RANO) group has given guidance on response assessment, trial design, and trial procedures to improve and standardize the way clinical trials in neurooncological studies ... Full text Link to item Cite

A peptide vaccine targeting the CMV antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma: a phase 1 trial.

Journal article Nat Cancer · September 2025 The human cytomegalovirus (CMV) antigen pp65 is expressed in high-grade glioma (HGG) and medulloblastoma but not in the adjacent brain. This single-arm phase 1 trial ( NCT03299309 ) assessed the safety and immunogenicity of a peptide vaccine (PEP-CMV) targ ... Full text Open Access Link to item Cite

Phase II randomized glioma study to evaluate efficacy and satisfaction of rolapitant plus ondansetron in preventing chemoradiation-induced nausea and vomiting.

Journal article Neurooncol Pract · August 2025 BACKGROUND: Nausea and vomiting remain feared cancer treatment-related side effects. Antiemetic guideline trials exclude malignant glioma patients. In patients receiving radiation with concurrent temozolomide, chemoradiation-induced nausea; vomiting (cRINV ... Full text Open Access Link to item Cite

Predicting therapeutic clinical trial enrollment for adult patients with low- and high-grade glioma using supervised machine learning.

Journal article Sci Adv · June 6, 2025 Therapeutic clinical trial enrollment does not match glioma incidence across demographics. Traditional statistical methods have identified independent predictors of trial enrollment; however, our understanding of the interactions between these factors rema ... Full text Link to item Cite

A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine.

Journal article Nat Commun · August 11, 2024 Current treatment outcome of patients with glioblastoma (GBM) remains poor. Following standard therapy, recurrence is universal with limited survival. Tumors from 173 GBM patients are analysed for somatic mutations to generate a personalized peptide vaccin ... Full text Link to item Cite

Use, access, and initial outcomes of off-label ivosidenib in patients with IDH1 mutant glioma.

Journal article Neurooncol Pract · April 2024 BACKGROUND: Isocitrate dehydrogenase (IDH) is commonly mutated (mIDH) in gliomas, and this mutant enzyme produces the oncometabolite 2-hydroxyglutarate (2HG). 2HG promotes gliomagenesis and is implicated in epileptogenesis. Ivosidenib (IVO), a small molecu ... Full text Open Access Link to item Cite

Correcting the drug development paradigm for glioblastoma requires serial tissue sampling.

Journal article Nat Med · October 2023 A breakthrough in drug discovery for glioblastoma requires serial collection of tissue from the central nervous system via window of opportunity trials ... Full text Link to item Cite

Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial.

Journal article Lancet Child Adolesc Health · July 2023 BACKGROUND: Outcomes of recurrent paediatric high-grade glioma are poor, with a median overall survival of less than 6 months. Viral immunotherapy, such as the polio-rhinovirus chimera lerapolturev, is a novel approach for treatment of recurrent paediatric ... Full text Link to item Cite

Intratumor childhood vaccine-specific CD4+ T-cell recall coordinates antitumor CD8+ T cells and eosinophils.

Journal article J Immunother Cancer · April 2023 BACKGROUND: Antitumor mechanisms of CD4+ T cells remain crudely defined, and means to effectively harness CD4+ T-cell help for cancer immunotherapy are lacking. Pre-existing memory CD4+ T cells hold potential to be leveraged for this purpose. Moreover, the ... Full text Link to item Cite

Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models.

Journal article Sci Transl Med · February 8, 2023 D2C7-immunotoxin (IT), a dual-specific IT targeting wild-type epidermal growth factor receptor (EGFR) and mutant EGFR variant III (EGFRvIII) proteins, demonstrates encouraging survival outcomes in a subset of patients with glioblastoma. We hypothesized tha ... Full text Link to item Cite

Oncolytic Viral Therapy for Malignant Glioma and Their Application in Clinical Practice.

Journal article Neurotherapeutics · October 2022 Glioblastoma is the most common primary malignant brain tumor in adults and outcomes remain poor despite the current standard of care multimodal therapy. Oncolytic virotherapy utilizes engineered viruses to exert an anti-tumor effect via both direct oncoly ... Full text Link to item Cite

Effects of low-dose naltrexone on quality of life in high-grade glioma patients: a placebo-controlled, double-blind randomized trial.

Journal article Support Care Cancer · April 2022 PURPOSE: At diagnosis and throughout the disease course, patients with high-grade glioma (HGG) experience a diminished quality of life (QOL) and increased fatigue. Naltrexone, an orally semisynthetic opiate antagonist, is FDA-approved for the treatment of ... Full text Link to item Cite

Convection-enhanced delivery for high-grade glioma.

Journal article Neurooncol Pract · February 2022 Glioblastoma (GBM) is the most common adult primary malignant brain tumor and is associated with a dire prognosis. Despite multi-modality therapies of surgery, radiation, and chemotherapy, its 5-year survival rate is 6.8%. The presence of the blood-brain b ... Full text Link to item Cite

Long-Term Outcomes for Patients With Atypical or Malignant Meningiomas Treated With or Without Radiation Therapy: A 25-Year Retrospective Analysis of a Single-Institution Experience.

Journal article Adv Radiat Oncol · 2022 PURPOSE: Atypical (World Health Organization [WHO] grade 2) and malignant (WHO grade 3) meningiomas have high rates of local recurrence, and questions remain about the role of adjuvant radiation therapy (RT) for patients with WHO grade 2 disease. These pat ... Full text Link to item Cite

Primary brain tumor patients admitted to a US intensive care unit: a descriptive analysis.

Journal article CNS Oncol · September 1, 2021 Purpose: To describe our population of primary brain tumor (PBT) patients, a subgroup of cancer patients whose intensive care unit (ICU) outcomes are understudied. Methods: Retrospective analysis of PBT patients admitted to an ICU between 2013 to 2018 for ... Full text Open Access Link to item Cite

Repeatability of Automated Image Segmentation with BraTumIA in Patients with Recurrent Glioblastoma.

Journal article AJNR Am J Neuroradiol · June 2021 BACKGROUND AND PURPOSE: Despite high interest in machine-learning algorithms for automated segmentation of MRIs of patients with brain tumors, there are few reports on the variability of segmentation results. The purpose of this study was to obtain benchma ... Full text Link to item Cite

Spiritual well-being and its association with health-related quality of life in primary brain tumor patients.

Journal article Neurooncol Pract · June 2021 BACKGROUND: Spirituality can impact patients' attitudes and decisions about treatment and end-of-life care when coping with cancer. Previous studies documented health-related quality of life (HRQoL) and spiritual well-being (SWB) as positively correlated w ... Full text Link to item Cite

Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.

Journal article Nat Commun · January 13, 2021 Several immunotherapy clinical trials in recurrent glioblastoma have reported long-term survival benefits in 10-20% of patients. Here we perform genomic analysis of tumor tissue from recurrent WHO grade IV glioblastoma patients acquired prior to immunother ... Full text Open Access Link to item Cite

Adjuvant Radiation in Older Patients With Glioblastoma: A Retrospective Single Institution Analysis.

Journal article Front Oncol · 2021 OBJECTIVES: Standard 6-week and hypofractionated 3-week courses of adjuvant radiation therapy (RT) are both options for older patients with glioblastoma (GBM), but deciding the optimal regimen can be challenging. This analysis explores clinical factors ass ... Full text Open Access Link to item Cite

Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data.

Journal article Neurooncol Adv · 2021 BACKGROUND: This phase I/II trial in patients with recurrent glioblastoma (GBM) evaluates the safety and preliminary efficacy of marizomib, an irreversible pan-proteasome inhibitor that crosses the blood-brain barrier. METHODS: Part A assessed the safety a ... Full text Link to item Cite

Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.

Journal article Invest New Drugs · October 2020 Purpose Galunisertib, a TGF-β inhibitor, has demonstrated antitumor effects in preclinical and radiographic responses in some patients with malignant glioma. This Phase 1b/2a trial investigated the clinical benefit of combining galunisertib with temozolomi ... Full text Link to item Cite

Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.

Journal article Support Care Cancer · May 2020 PURPOSE: CINV remains a distressing side effect experienced by glioma patients receiving multi-day temozolomide therapy, in spite of guideline-based antiemetic therapy with selective serotonin-receptor-antagonists. Antiemetic research with aprepitant has r ... Full text Link to item Cite

Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series.

Journal article J Neurooncol · April 2020 PURPOSE: Primary central nervous system lymphoma (PCNSL) is a subtype of non-Hodgkin's lymphoma that involves the brain, spinal cord, or leptomeninges, without evidence of systemic disease. This rare disease accounts for ~ 3% of all primary central nervous ... Full text Open Access Link to item Cite

Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial.

Journal article Clin Cancer Res · April 1, 2020 PURPOSE: Rindopepimut is a vaccine targeting the tumor-specific EGF driver mutation, EGFRvIII. The ReACT study investigated whether the addition of rindopepimut to standard bevacizumab improved outcome for patients with relapsed, EGFRvIII-positive glioblas ... Full text Link to item Cite

The role of chemotherapy in the treatment of central neurocytoma.

Journal article CNS Oncol · November 1, 2019 Aim: Central neurocytoma (CN) is a rare WHO grade II central nervous system (CNS) tumor. This is an update on chemotherapeutic agents used in its treatment. Patients & methods: An institutional review board-approved, chart review of patients seen at our in ... Full text Open Access Link to item Cite

Second primary cancers in long-term survivors of glioblastoma.

Journal article Neurooncol Pract · September 2019 BACKGROUND: Overall survival (OS) in glioblastoma (GBM) is poor at an average of 14 to 18 months, and long-term survivors (LTS) of GBM are rare. LTS of GBM, defined as surviving >5 years postdiagnosis, represent only 2% to 10% of all GBM patients. LTS of c ... Full text Link to item Cite

Complementary and integrative health interventions and their association with health-related quality of life in the primary brain tumor population.

Journal article Complement Ther Clin Pract · August 2019 BACKGROUND AND PURPOSE: Little is known about complementary and integrative health intervention usage in the primary brain tumor population. We aimed to identify the percentage of patients using these practices and explore the impact on quality of life. MA ... Full text Link to item Cite

Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations.

Journal article J Immunother Cancer · May 29, 2019 BACKGROUND: D2C7-IT is a novel immunotoxin (IT) targeting wild-type epidermal growth factor receptor (EGFRwt) and mutant EGFR variant III (EGFRvIII) proteins in glioblastoma. In addition to inherent tumoricidal activity, immunotoxins induce secondary immun ... Full text Open Access Link to item Cite

Single-institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice.

Journal article Health Sci Rep · April 2019 BACKGROUND AND AIMS: This retrospective review of patients with recurrent glioblastoma treated at the Preston Robert Tisch Brain Tumor Center investigated treatment patterns, survival, and safety with bevacizumab in a real-world setting. METHODS: Adult pat ... Full text Link to item Cite

Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.

Journal article Neuro Oncol · September 3, 2018 BACKGROUND: To overcome challenges with traditional response assessment in anti-angiogenic agents, the current study uses T1 subtraction maps to quantify volumetric radiographic response in monotherapy with cabozantinib, an orally bioavailable tyrosine kin ... Full text Link to item Cite

Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma.

Journal article Oncologist · August 2018 LESSONS LEARNED: Due to evolving imaging criteria in brain tumors and variation in magnetic resonance imaging evaluation, it is not ideal to use response rate as a primary objective. Future studies involving antiangiogenic agents should use overall surviva ... Full text Link to item Cite

Recurrent Glioblastoma Treated with Recombinant Poliovirus.

Journal article N Engl J Med · July 12, 2018 BACKGROUND: The prognosis of patients with recurrent World Health Organization (WHO) grade IV malignant glioma is dismal, and there is currently no effective therapy. We conducted a dose-finding and toxicity study in this population of patients, evaluating ... Full text Link to item Cite

Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.

Journal article J Neurooncol · July 2018 BACKGROUND: Sym004 is a mixture of two monoclonal antibodies (mAbs), futuximab and modotuximab, targeting non-overlapping epitopes on the epidermal growth factor receptor (EGFR). Previous studies have shown that Sym004 is more efficient at inducing interna ... Full text Open Access Link to item Cite

Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.

Journal article J Neurooncol · April 2018 Prognosis of recurrent glioblastoma (GBM) is poor with 6-month progression-free survival (PFS6) ranging from 9 to 48% depending on the treatment regimen and use of anti-angiogenic therapies. We sought to study vorinostat (VOR), a histone deacetylase inhibi ... Full text Link to item Cite

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy.

Journal article Neuro Oncol · January 22, 2018 BACKGROUND: Cabozantinib is a potent, multitarget inhibitor of MET and vascular endothelial growth factor receptor 2 (VEGFR2). This open-label, phase II trial evaluated cabozantinib in patients with recurrent or progressive glioblastoma (GBM). METHODS: Pat ... Full text Link to item Cite

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy.

Journal article Neuro Oncol · January 22, 2018 BACKGROUND: Cabozantinib is a tyrosine kinase inhibitor with activity against vascular endothelial growth factor receptor 2 (VEGFR2) and MET that has demonstrated clinical activity in advanced solid tumors. This open-label, phase II trial evaluated cabozan ... Full text Link to item Cite

Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma.

Journal article Cancer Res · January 1, 2018 Median survival for glioblastoma (GBM) remains <15 months. Human cytomegalovirus (CMV) antigens have been identified in GBM but not normal brain, providing an unparalleled opportunity to subvert CMV antigens as tumor-specific immunotherapy targets. A recen ... Full text Link to item Cite

Adjunctive perampanel for glioma-associated epilepsy.

Journal article Epilepsy Behav Case Rep · 2018 Glioma-associated epilepsy is associated with excessive glutamate signaling. We hypothesized that perampanel, an amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptor antagonist, would treat glioma-related epilepsy. We conducted ... Full text Link to item Cite

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.

Journal article Lancet Oncol · October 2017 BACKGROUND: Rindopepimut (also known as CDX-110), a vaccine targeting the EGFR deletion mutation EGFRvIII, consists of an EGFRvIII-specific peptide conjugated to keyhole limpet haemocyanin. In the ACT IV study, we aimed to assess whether or not the additio ... Full text Link to item Cite

A cross sectional analysis from a single institution's experience of psychosocial distress and health-related quality of life in the primary brain tumor population.

Journal article J Neurooncol · September 2017 Primary brain tumor patients experience high levels of distress. The purpose of this cross-sectional, retrospective study is to evaluate the level and different sources of psychosocial distress and how these pertain to health-related quality of life (HRQoL ... Full text Link to item Cite

A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab.

Journal article Ther Clin Risk Manag · 2017 PURPOSE: Given that the prognosis of recurrent malignant glioma (MG) remains poor, improving quality of life (QoL) through symptom management is important. Meta-analyses establishing antiemetic guidelines have demonstrated the superiority of palonosetron ( ... Full text Link to item Cite

Vaccine Therapy, Oncolytic Viruses, and Gliomas.

Journal article Oncology (Williston Park) · March 2016 After years of active research and refinement, vaccine therapy and oncolytic viruses are becoming part of the arsenal in the treatment of gliomas. In contrast to standard treatment with radiation therapy and chemotherapy, vaccines are more specific to the ... Link to item Cite

Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.

Journal article Cancer · February 15, 2016 BACKGROUND: Cabozantinib inhibits mesenchymal-epithelial transition factor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2) and has demonstrated activity in patients with recurrent glioblastoma, warranting evaluation of the addition of cabo ... Full text Link to item Cite

CCR 20th Anniversary Commentary: Bevacizumab in the Treatment of Glioblastoma--The Progress and the Limitations.

Journal article Clin Cancer Res · October 1, 2015 Vredenburgh and colleagues conducted the first phase II study of bevacizumab plus irinotecan in recurrent malignant glioma, confirming the safety and efficacy of bevacizumab. This study, which was published in the February 15, 2007, issue of Clinical Cance ... Full text Link to item Cite

Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.

Journal article J Clin Oncol · August 20, 2015 PURPOSE: Two phase II studies assessed the efficacy of vismodegib, a sonic hedgehog (SHH) pathway inhibitor that binds smoothened (SMO), in pediatric and adult recurrent medulloblastoma (MB). PATIENTS AND METHODS: Adult patients enrolled onto PBTC-025B and ... Full text Link to item Cite

Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma.

Journal article Oncologist · July 2015 LESSONS LEARNED: Trials focusing on unresectable multifocal glioblastoma are needed because of the extremely poor prognosis and challenges in receiving standard therapy, such as concurrent radiation and chemotherapy.Developing a strategy to chemically debu ... Full text Link to item Cite

Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide.

Journal article Cancer Immunol Res · April 2015 Therapeutic vaccination of patients with cancer-targeting tumor-associated antigens is a promising strategy for the specific eradication of invasive malignancies with minimal toxicity to normal tissues. However, as increasingly potent modalities for stimul ... Full text Link to item Cite

Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients.

Journal article Nature · March 19, 2015 After stimulation, dendritic cells (DCs) mature and migrate to draining lymph nodes to induce immune responses. As such, autologous DCs generated ex vivo have been pulsed with tumour antigens and injected back into patients as immunotherapy. While DC vacci ... Full text Open Access Link to item Cite

Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patients.

Journal article J Neurooncol · December 2014 Quality of life (QoL) impairment and fatigue are frequently experienced during treatment for recurrent high-grade glioma (HGG). Fatigue and QoL impairments can be due to primary neurological dysfunction, cytotoxic treatments, mood disturbances, and support ... Full text Link to item Cite

Oncolytic polio virotherapy of cancer.

Journal article Cancer · November 1, 2014 Recently, the century-old idea of targeting cancer with viruses (oncolytic viruses) has come of age, and promise has been documented in early stage and several late-stage clinical trials in a variety of cancers. Although originally prized for their direct ... Full text Link to item Cite

Oncolytic polio/rhinovirus recombinant (pvsripo) in recurrent glioblastoma (gbm): first phase I clinical trial evaluating the intratumoral administration.

Journal article Neuro Oncol · July 2014 PVSRIPO is the live attenuated, oral (SABIN) serotype 1 poliovirus vaccine containing a heterologous internal ribosomal entry site stemming from human rhinovirus type 2. PVSRIPO recognizes nectin-like molecule-5, an oncofetal cell adhesion molecule and tum ... Full text Link to item Cite

Oncolytic poliovirus immunotherapy of glioblastoma.

Journal article Neuro Oncol · July 2014 With the exception of Burkitt lymphoma, almost all solid cancers are susceptible to infection with poliovirus, due to widespread ectopic expression of the poliovirus receptor, the onco-fetal cell adhesion molecule Necl5/CD155. We engineered a profoundly CN ... Full text Link to item Cite

Imaging descriptors improve the predictive power of survival models for glioblastoma patients.

Journal article Neuro Oncol · October 2013 BACKGROUND: Because effective prediction of survival time can be highly beneficial for the treatment of glioblastoma patients, the relationship between survival time and multiple patient characteristics has been investigated. In this paper, we investigate ... Full text Link to item Cite

Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial.

Journal article Int J Radiat Oncol Biol Phys · August 1, 2013 PURPOSE: Virtually all patients with malignant glioma (MG) eventually recur. This study evaluates the safety of concurrent stereotactic radiosurgery (SRS) and bevacizumab (BVZ), an antiangiogenic agent, in treatment of recurrent MG. METHODS AND MATERIALS: ... Full text Link to item Cite

O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma.

Journal article J Neurooncol · August 2013 Temozolomide, an alkylating agent, has shown promise in treating primary central nervous system lymphoma (PCNSL). The enzyme O(6)-methylguanine-DNA methyltransferase (MGMT) repairs alkylating damage, such as that induced by temozolomide. We hypothesized th ... Full text Link to item Cite

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.

Journal article Cancer Med · April 2013 Patients with unresectable glioblastomas have a poor prognosis, with median survival of 6-10 months. We conducted a phase II trial of upfront 5-day temozolomide (TMZ) and bevacizumab (BV) in patients with newly diagnosed unresectable or multifocal glioblas ... Full text Open Access Link to item Cite

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients.

Journal article Br J Cancer · October 23, 2012 BACKGROUND: Bevacizumab improves outcome for most recurrent glioblastoma patients, but the duration of benefit is limited and survival after initial bevacizumab progression is poor. We evaluated bevacizumab continuation beyond initial progression among rec ... Full text Open Access Link to item Cite

Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.

Journal article Cancer · October 1, 2012 BACKGROUND: We evaluated the efficacy of imatinib plus hydroxyurea in patients with progressive/recurrent low-grade glioma. METHODS: A total of 64 patients with recurrent/progressive low-grade glioma were enrolled in this single-center study that stratifie ... Full text Link to item Cite

Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.

Journal article J Neurooncol · August 2012 Intracranial meningiomas are often indolent tumors which typically grow over years to decades. Nonetheless, meningiomas that progress after maximum safe resection and radiation therapy pose a significant therapeutic challenge and effective therapies have y ... Full text Link to item Cite

Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.

Journal article J Neurooncol · July 2012 To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of dasatinib, an inhibitor of the Src family kinase proteins, with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, among recurrent malignant glioma pat ... Full text Link to item Cite

Adjuvant PCV chemo hikes oligodendroglioma survival: Commentary

Journal article Oncology Report · July 1, 2012 Cite

A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme.

Journal article Br J Radiol · April 2012 OBJECTIVES: The aim of this study was to determine the prognostic significance of changes in parameters derived from diffusion tensor imaging (DTI) that occur in response to treatment with bevacizumab and irinotecan in patients with recurrent glioblastoma ... Full text Link to item Cite

A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression.

Journal article J Neurooncol · April 2012 This phase II trial was undertaken to evaluate the efficacy of TLN-4601 in patients with glioblastoma (GBM) at first progression. TLN-4601 inhibits the Ras-MAPK signaling pathway, and in animal models crosses the blood-brain barrier and accumulates in impl ... Full text Link to item Cite

Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.

Journal article Int J Radiat Oncol Biol Phys · April 1, 2012 PURPOSE: Patients with recurrent malignant gliomas treated with stereotactic radiosurgery (SRS) and multiagent systemic therapies were reviewed to determine the effects of patient- and treatment-related factors on survival and toxicity. METHODS AND MATERIA ... Full text Link to item Cite

Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.

Journal article J Neurooncol · March 2012 We evaluated the efficacy of carboplatin, irinotecan, and bevacizumab among bevacizumab-naïve, recurrent glioblastoma (GBM) patients in a phase 2, open-label, single arm trial. Forty eligible patients received carboplatin (area under the plasma curve [AUC] ... Full text Link to item Cite

Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients.

Journal article J Neurooncol · March 2012 Although outcome following bevacizumab among recurrent grade IV malignant glioma patients is documented as poor by several analyses, outcome for recurrent grade III patients following bevacizumab therapy has not been specifically evaluated. We performed a ... Full text Link to item Cite

Bevacizumab and daily temozolomide for recurrent glioblastoma.

Journal article Cancer · March 1, 2012 BACKGROUND: The authors performed a phase 2 trial of combined protracted daily temozolomide and biweekly bevacizumab for patients with recurrent glioblastoma who had previously received radiation therapy and temozolomide. METHODS: There was no limit on the ... Full text Link to item Cite

Avastin: more questions than answers. .

Journal article J Neurosurg · February 2012 Full text Link to item Cite

Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.

Journal article Int J Radiat Oncol Biol Phys · January 1, 2012 PURPOSE: To determine the safety of the addition of bevacizumab to standard radiation therapy and daily temozolomide for newly diagnosed glioblastoma multiforme (GBM). METHODS AND MATERIALS: A total of 125 patients with newly diagnosed GBM were enrolled in ... Full text Link to item Cite

A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma.

Journal article PLoS One · 2012 BACKGROUND: Preclinical studies in mice have demonstrated that the prophylactic depletion of immunosuppressive regulatory T-cells (T(Regs)) through targeting the high affinity interleukin-2 (IL-2) receptor (IL-2Rα/CD25) can enhance anti-tumor immunotherapy ... Full text Open Access Link to item Cite

Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.

Journal article J Neurooncol · January 2012 We prospectively evaluated the efficacy and safety of imatinib plus hydroxyurea in patients with progressive/recurrent meningioma. A total of 21 patients with progressive/recurrent meningioma were enrolled in this dual center, single-arm, phase II trial. A ... Full text Link to item Cite

Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.

Journal article J Neurooncol · December 2011 We determined the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of the oral vascular endothelial growth factor receptor (VEGFR) inhibitor, sunitinib, when administered with irinotecan among recurrent malignant glioma (MG) patients. For ea ... Full text Link to item Cite

Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.

Journal article Cancer · December 1, 2011 BACKGROUND: The efficacy of carboplatin, irinotecan, and bevacizumab among recurrent glioblastoma (GBM) patients after prior progression on bevacizumab therapy in a phase 2, open-label, single-arm trial was evaluated. METHODS: Eligible patients received ca ... Full text Link to item Cite

A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma.

Journal article J Neurooncol · December 2011 We conducted a phase I clinical trial of the combination of SCH 66336 with temozolomide administered on the standard 5-day dosing schedule. The primary objective was to determine the maximum tolerated dose and dose limiting toxicity (DLT) of twice daily SC ... Full text Link to item Cite

Everolimus tablets for patients with subependymal giant cell astrocytoma.

Journal article Expert Opin Pharmacother · October 2011 INTRODUCTION: Better understanding of aberrantly active molecular pathways in tumors offers potential to develop more specific and less toxic therapies. Abnormal mammalian target of rapamycin (mTOR) complex signaling and defects in TSC1 and TSC2 have been ... Full text Link to item Cite

Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.

Journal article Blood · September 15, 2011 Lymphodepletion augments adoptive cell transfer during antitumor immunotherapy, producing dramatic clinical responses in patients with malignant melanoma. We report that the lymphopenia induced by the chemotherapeutic agent temozolomide (TMZ) enhances vacc ... Full text Link to item Cite

Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma.

Journal article J Clin Oncol · July 20, 2011 PURPOSE: Identifying strong markers of prognosis are critical to optimize treatment and survival outcomes in patients with malignant recurrent glioma. We investigated the prognostic significance of exercise behavior and functional capacity in this populati ... Full text Link to item Cite

The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.

Journal article Clin Cancer Res · June 15, 2011 PURPOSE: To determine if the addition of bevacizumab to radiation therapy and temozolomide, followed by bevacizumab, temozolomide, and irinotecan, for newly diagnosed glioblastoma patients is safe and effective. EXPERIMENTAL DESIGN: A total of 75 patients ... Full text Link to item Cite

Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.

Journal article J Neurooncol · June 2011 We evaluated the efficacy of metronomic etoposide or temozolomide administered with bevacizumab among recurrent glioblastoma (GBM) patients who progressed on prior bevacizumab therapy in a phase 2, open-label, two-arm trial. Twenty-three patients received ... Full text Link to item Cite

A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.

Journal article J Natl Compr Canc Netw · April 2011 Glioblastoma, the most common primary malignant brain tumor among adults, is a highly angiogenic and deadly tumor. Angiogenesis in glioblastoma, driven by hypoxia-dependent and independent mechanisms, is primarily mediated by vascular endothelial growth fa ... Full text Link to item Cite

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.

Journal article Neuro Oncol · March 2011 Epidermal growth factor receptor variant III (EGFRvIII) is a tumor-specific mutation widely expressed in glioblastoma multiforme (GBM) and other neoplasms, but absent from normal tissues. Immunotherapeutic targeting of EGFRvIII could eliminate neoplastic c ... Full text Link to item Cite

A novel method for volumetric MRI response assessment of enhancing brain tumors.

Journal article PLoS One · January 26, 2011 Current radiographic response criteria for brain tumors have difficulty describing changes surrounding postoperative resection cavities. Volumetric techniques may offer improved assessment, however usually are time-consuming, subjective and require expert ... Full text Link to item Cite

Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.

Journal article J Neurooncol · January 2011 Sorafenib, an oral VEGFR-2, Raf, PDGFR, c-KIT and Flt-3 inhibitor, is active against renal cell and hepatocellular carcinomas, and has recently demonstrated promising activity for lung and breast cancers. In addition, various protracted temozolomide dosing ... Full text Link to item Cite

Primary intracerebral Hodgkin lymphoma with recurrence.

Journal article Clin Neuropathol · 2011 OBJECTIVE: To report a case of primary intracerebral Hodgkin lymphoma with disease recurrence. METHODS: Case report and review of the literature. RESULTS: A 58-year-old immunocompetent male presented with aphasia. Neuroimaging revealed a left temporal lobe ... Full text Link to item Cite

Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy.

Journal article J Neurooncol · January 2011 Striae distensae (stretch marks) are a common complication seen in patients on chronic corticosteroid therapy. Under certain circumstances, primary brain tumor patients require chronic corticosteroid therapy and can suffer from striae distensae. Bevacizuma ... Full text Link to item Cite

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.

Journal article Neuro Oncol · December 2010 Vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) signaling are established contributors to malignant glioma (MG) biology. We, therefore, evaluated bevacizumab, a humanized anti-VEGF monoclonal antibody, in combination w ... Full text Link to item Cite

Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration.

Journal article J Neurooncol · July 2010 Temporal paragangliomas are highly vascular tumors treated primarily by surgical resection. However, surgery to remove these tumors is associated with significant morbidity, including cranial nerve dysfunction. Interestingly, these tumors have been shown t ... Full text Link to item Cite

Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.

Journal article J Neurooncol · January 2010 We evaluated the anti-tumor activity and safety of erlotinib, a receptor tyrosine kinase inhibitor of the epidermal growth factor receptor, plus sirolimus, an inhibitor of the mammalian target of rapamycin, among patients with recurrent glioblastoma (GBM) ... Full text Link to item Cite

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.

Journal article Br J Cancer · December 15, 2009 BACKGROUND: We evaluated bevacizumab with metronomic etoposide among recurrent malignant glioma patients in a phase 2, open-label trial. METHODS: A total of 59 patients, including 27 with glioblastoma (GBM) and 32 with grade 3 malignant glioma, received 10 ... Full text Open Access Link to item Cite

Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.

Journal article J Neurooncol · December 2009 This phase II trial evaluated efficacy and safety of temozolomide (TMZ) in combination with irinotecan (CPT-11) before radiotherapy in patients with newly diagnosed glioblastoma multiforme (GBM). Prior to radiotherapy, patients were treated with a maximum ... Full text Link to item Cite

Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients.

Journal article J Neurooncol · October 2009 The purpose of this study was to determine the safety of tinzaparin for deep vein thrombosis prophylaxis in newly diagnosed grade III-IV malignant glioma patients. Patients were initiated on daily tinzaparin at a fixed dose of 4,500 IU subcutaneously betwe ... Full text Link to item Cite

Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.

Journal article Neuro Oncol · October 2009 This phase I clinical trial conducted with patients who had recurrent or progressive malignant glioma (MG) was designed to determine the maximum tolerated dose (MTD) and toxicity of three different 5-day dosing regimens of temozolomide (TMZ) in combination ... Full text Link to item Cite

Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.

Journal article Cancer · August 1, 2009 BACKGROUND: Glioblastoma multiforme (GBM), the most lethal type of brain tumor, has a 1-year median survival. The effect of carmustine wafers on the survival of newly diagnosed GBM patients treated with radiotherapy (RT) and concurrent temozolomide (TMZ) p ... Full text Link to item Cite

Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing.

Journal article J Neurooncol · August 2009 BACKGROUND: Performance status (PS) scoring systems are tools of immense clinical importance in the management of patients with malignant disease but these tools are subjective and do not provide an objective evaluation of physical functioning. We conducte ... Full text Link to item Cite

Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.

Journal article Cancer · July 1, 2009 BACKGROUND: The current study was a phase 1 clinical trial conducted with patients who had recurrent or progressive malignant glioma (MG). The trial was designed to determine the maximum tolerated dose (MTD) and toxicity of irinotecan (CPT-11) when adminis ... Full text Link to item Cite

Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.

Journal article Cancer · May 15, 2009 BACKGROUND: This study determined the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of the oral vascular endothelial growth factor receptor (VEGFR) inhibitor, vatalanib, when administered with imatinib and hydroxyurea on a continuous dail ... Full text Link to item Cite

Repeatability of quantitative parameters derived from diffusion tensor imaging in patients with glioblastoma multiforme.

Journal article J Magn Reson Imaging · May 2009 PURPOSE: To quantify the repeatability of apparent diffusion coefficient (ADC) and fractional anisotropy (FA) in patients with glioblastoma multiforme. MATERIALS AND METHODS: IRB approval and informed consent were obtained for this Health Insurance Portabi ... Full text Link to item Cite

Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.

Journal article J Clin Oncol · March 10, 2009 PURPOSE: This phase II trial was designed to define the role of O(6)-benzylguanine (O(6)-BG) in restoring temozolomide sensitivity in patients with recurrent or progressive, temozolomide-resistant malignant glioma and to evaluate the safety of administerin ... Full text Link to item Cite

Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.

Journal article Clin Cancer Res · February 1, 2009 PURPOSE: This phase II trial was designed to define the efficacy of Gliadel wafers in combination with an infusion of O6-benzylguanine (O6-BG) that suppresses tumor O6-alkylguanine-DNA alkyltransferase (AGT) levels in patients with recurrent glioblastoma m ... Full text Link to item Cite

Experience with irinotecan for the treatment of malignant glioma.

Journal article Neuro Oncol · February 2009 Malignant glioma is the most commonly occurring primary malignant brain tumor. It is difficult to treat and is usually associated with an inexorable, rapidly fatal clinical course. Chemotherapy, radiotherapy, and surgical excision are core components in th ... Full text Link to item Cite

Current available therapies and future directions in the treatment of malignant gliomas.

Journal article Biologics · 2009 The prognosis of patients diagnosed with malignant glioma (MG) remains poor. However, recent advances in neuro-oncology allowing a better understanding of this particular disease have allowed the development of new therapeutics. Many molecular genetic and ... Link to item Cite

In reply

Journal article Journal of Clinical Oncology · November 10, 2008 Full text Cite

Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.

Journal article Clin Cancer Res · November 1, 2008 PURPOSE: Although patients with newly diagnosed WHO grade 3 malignant glioma have a more favorable prognosis than those with WHO grade 4 malignant glioma, salvage therapies following recurrence offer essentially palliative benefit. We did a phase II trial ... Full text Link to item Cite

Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma.

Journal article Neuro Oncol · October 2008 The efficacy of high-dose chemotherapy (HDC) or standard salvage therapy was evaluated in patients with recurrent medulloblastoma (MBL) using retrospective chart review of all patients with recurrent MBL treated at Duke University Medical Center between 19 ... Full text Link to item Cite

Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.

Journal article Neuro Oncol · June 2008 We determined the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of imatinib mesylate, an inhibitor of the receptor tyrosine kinases platelet-derived growth factor receptor (PDGFR), the proto-oncogene product c-kit, and the fusion protein Bc ... Full text Link to item Cite

Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma.

Journal article Expert Rev Anticancer Ther · May 2008 Angiogenesis, the growth of new blood vessels from previously existing vasculature, is a requirement for tumor growth and metastasis. The first US FDA-approved drugs targeting angiogenesis have shown potential in the treatment of malignant gliomas. Immunot ... Full text Link to item Cite

A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.

Journal article Neuro Oncol · April 2008 The purpose of this study was to determine the feasibility and assess the efficacy and toxicity, among newly diagnosed malignant glioma patients, of administering (131)I-labeled murine antitenascin monoclonal antibody 81C6 ((131)I-81C6) into a surgically c ... Full text Link to item Cite

Irinotecan and bevacizumab for the treatment of recurrent glioblastoma multiforme

Journal article American Journal of Hematology Oncology · April 1, 2008 Cite

Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy.

Journal article Expert Opin Biol Ther · April 2008 BACKGROUND: Adults with malignant glioma, especially the most common subtype, glioblastoma multiforme, have an unacceptably poor outcome with current therapies. Malignant gliomas are amongst the most angiogenic of cancers, and VEGF is the dominant angiogen ... Full text Link to item Cite

In reply

Journal article Journal of Clinical Oncology · February 20, 2008 Full text Cite

The emerging role of anti-angiogenic therapy for malignant glioma.

Journal article Curr Treat Options Oncol · February 2008 Adults with glioblastoma multiforme (GBM), the most common primary brain tumor, have an unacceptably poor outcome with conventional cytotoxic therapies. Malignant gliomas are remarkably angiogenic, and vascular endothelial growth factor (VEGF) is the domin ... Full text Link to item Cite

Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.

Journal article J Clin Oncol · January 10, 2008 PURPOSE: The combination of a vascular endothelial growth factor (VEGF) -neutralizing antibody, bevacizumab, and irinotecan is associated with high radiographic response rates and improved survival outcomes in patients with recurrent malignant gliomas. The ... Full text Link to item Cite

[Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study].

Journal article Rev Neurol (Paris) · 2008 RATIONALE: Second-line chemotherapy is disappointing in recurrent high-grade gliomas. Dramatic responses in recurrent high-grade gliomas have been reported in a recent monocentric trial with a novel association combining bevacizumab (anti-VEGF monoclonal a ... Full text Link to item Cite

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

Journal article J Clin Oncol · October 20, 2007 PURPOSE: The prognosis for patients with recurrent glioblastoma multiforme is poor, with a median survival of 3 to 6 months. We performed a phase II trial of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in combination with irin ... Full text Link to item Cite

Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas.

Journal article Ther Clin Risk Manag · October 2007 Malignant gliomas represent the majority of primary brain tumors, and the prognosis of the patients afflicted with these tumors has been historically dismal, with almost uniform progressive neurologic impairment and rapid death. Even with multimodal treatm ... Link to item Cite

Molecularly targeted therapy for malignant glioma.

Journal article Cancer · July 1, 2007 Malignant gliomas are relatively uncommon but lethal cancers. Despite recent research efforts in cancer therapy, the prognosis of patients with malignant gliomas has remained dismal. Understanding the molecular pathogenesis of glioma may lead to a rational ... Full text Link to item Cite

Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.

Journal article J Neurooncol · May 2007 PURPOSE: Recent reports demonstrate the activity of imatinib mesylate, an ATP-mimetic, tyrosine kinase inhibitor, plus hydroxyurea, a ribonucleotide reductase inhibitor, in patients with recurrent glioblastoma multiforme. We performed the current phase 2 s ... Full text Link to item Cite

Temozolomide in children with progressive low-grade glioma.

Journal article Neuro Oncol · April 2007 We conducted a phase II study to assess the efficacy of oral temozolomide (TMZ) in children with progressive low-grade glioma. Thirty eligible patients were enrolled on this study. Median age at enrollment was 10 years (range, 4-18 years). Eligible patient ... Full text Link to item Cite

Neurofibromatosis type 2.

Journal article Neurology · March 27, 2007 Full text Link to item Cite

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

Journal article Clin Cancer Res · February 15, 2007 PURPOSE: Recurrent grade III-IV gliomas have a dismal prognosis with minimal improvements in survival seen following currently available salvage therapy. This study was conducted to determine if the combination of a novel antiangiogenic therapy, bevacizuma ... Full text Link to item Cite

Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme.

Journal article Neuro Oncol · January 2007 Cloretazine (VNP40101M) is a newly synthesized alkylating agent belonging to a novel class of alkylating agents called 1,2-bis(sulfonyl)hydrazines. Agents that belong to this class do not produce vinylating and chloroethylating species, and hence this clas ... Full text Link to item Cite

Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.

Journal article J Nucl Med · June 2006 UNLABELLED: Results from animal experiments have shown that human IgG2/mouse chimeric antitenascin 81C6 (ch81C6) monoclonal antibody exhibited higher tumor accumulation and enhanced stability compared with its murine parent. Our objective was to determine ... Link to item Cite

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.

Journal article Clin Cancer Res · February 1, 2006 PURPOSE: To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of gefitinib, a receptor tyrosine kinase inhibitor of the epidermal growth factor receptor, plus sirolimus, an inhibitor of the mammalian target of rapamycin, among pat ... Full text Link to item Cite

Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.

Journal article J Clin Oncol · January 1, 2006 PURPOSE: To assess the efficacy and toxicity of intraresection cavity iodine-131-labeled murine antitenascin monoclonal antibody 81C6 (131I-m81C6) among recurrent malignant brain tumor patients. PATIENTS AND METHODS: In this phase II trial, 100 mCi of 131I ... Full text Link to item Cite

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.

Journal article J Clin Oncol · December 20, 2005 PURPOSE: We performed a phase II study to evaluate the combination of imatinib mesylate, an adenosine triphosphate mimetic, tyrosine kinase inhibitor, plus hydroxyurea, a ribonucleotide reductase inhibitor, in patients with recurrent glioblastoma multiform ... Full text Link to item Cite

Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.

Journal article Cancer · October 1, 2005 BACKGROUND: The authors determined the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of irinotecan (CPT-11), a topoisomerase I inhibitor, when administered with temozolomide among patients with recurrent malignant glioma (MG). METHODS: Pati ... Full text Link to item Cite

Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.

Journal article J Clin Oncol · October 1, 2005 PURPOSE: We conducted a two-phase clinical trial in patients with progressive malignant glioma (MG). The first phase of this trial was designed to determine the dose of O6-BG effective in producing complete depletion of tumor AGT activity for 48 hours. The ... Full text Link to item Cite

Chemotherapy and novel therapeutic approaches in malignant glioma.

Journal article Front Biosci · September 1, 2005 Glial neoplasms represent 0.5-1% of all cancers in most Western countries. Malignant gliomas are among the most devastating cancers, leading to death in most cases. They present unique challenges due to their location, aggressive biological behavior and di ... Full text Link to item Cite

Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience.

Journal article Cancer · June 15, 2005 BACKGROUND: The treatment of malignant brain tumors is hampered by the presence of the blood-brain barrier, which limits chemotherapy penetration to the central nervous system (CNS). In recent years, different strategies have been designed to circumvent th ... Full text Link to item Cite

Technical modification in the intracarotid chemotherapy and osmotic blood-brain barrier disruption procedure to prevent the relapse of carboplatin-induced orbital pseudotumor.

Journal article AJNR Am J Neuroradiol · May 2004 The blood-brain barrier disruption (BBBD) procedure is an established strategy to enhance drug delivery to brain tumors. Complication rates associated with this procedure are usually low, but when complications do occur, they usually mandate discontinuatio ... Link to item Cite